A random forest model to predict the efficacy of anti-PD-1/PD-L1 monoclonal antibody in lung adenocarcinoma

被引：0
|
作者：
Xie, Tongji
Li, Yan
Yang, Lin
Wu, Lige
Yuan, Hanqi
Ying, Jianming
Li Junling
Xing, Puyuan
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Dept Pathol, State Key Lab Mol Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20558
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer
    Shukuya, Takehito
    Carbone, David P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 976 - 988
  • [2] HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
    Funaishi, Kunihiko
    Yamaguchi, Kakuhiro
    Tanahashi, Hiroki
    Kurose, Koji
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Masuda, Takeshi
    Nakashima, Taku
    Iwamoto, Hiroshi
    Hamada, Hironobu
    Oga, Toru
    Oka, Mikio
    Hattori, Noboru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [3] Hepatoid adenocarcinoma of the lung with PD-L1 expression and the response to anti-PD-1 therapy: a case report
    Li, Yan
    Liu, Lili
    Wang, Dongfeng
    Tan, Xiaojing
    Sui, Yanmin
    Yang, Honglan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] Pneumonitis with anti-PD-1/PD-L1 therapy
    Naidoo, J.
    Cunningham, J.
    Woo, K. M.
    Hellmann, M. D.
    Postow, M. A.
    Drilon, A. E.
    Chaft, J. E.
    Lesokhin, A. M.
    Segal, N. H.
    Callahan, M. K.
    Rudin, C. M.
    Iyriboz, T.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S103 - S103
  • [5] Efficacy of Anti-PD-1/PD-L1 Monoclonal Antibody Treatment of Advanced NSCLC on Density and Distribution of Tumor Infiltrating T Cells
    Wang, Y.
    Wo, Y.
    Xue, X.
    Xue, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S333 - S333
  • [6] Impact of PD-L1 feedback modulation on the sensitivity of anti-PD-1/PD-L1
    Zhu, Jian
    Zhu, Rebecca L.
    CANCER RESEARCH, 2019, 79 (13)
  • [7] DNA DAMAGE RESPONSE ALTERATIONS PREDICT RESPONSES TO ANTI-PD-1/PD-L1
    不详
    CANCER DISCOVERY, 2018, 8 (05) : 527 - 527
  • [8] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
    Sui, Xinbing
    Ma, Junhong
    Han, Weidong
    Wang, Xian
    Fang, Yong
    Li, Da
    Pan, Hongming
    Zhang, Li
    ONCOTARGET, 2015, 6 (23) : 19393 - 19404
  • [9] Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
    Liu, Junjie
    Tao, Haisu
    Yuan, Tong
    Li, Jiang
    Li, Jian
    Liang, Huifang
    Huang, Zhiyong
    Zhang, Erlei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [10] Prospects of the potential strategies to improve the efficacy of anti-PD-1/PD-L1 therapy
    Yamaguchi, Hirohito
    Wang, Shao-Chun
    Hung, Mien-Chie
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (05):
12345